Market Overview

UPDATE: Covidien Raises FY13 Sales-Growth Forecast

Related COV
After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?
Medtronic CEO: Covidien Merger Has Accelerated Growth Strategy
Tracking The Hotchkis & Wiley Value Opportunities Fund: Q4 2014 Update (Seeking Alpha)

Covidien PLC (NYSE: COV) reported a 0.2% drop in its fiscal first-quarter profit and lifted raised its FY13 sales forecast.

Covidien now expects a 5% to 8% rise in its FY13 sales, versus its September view of 3% to 6% sales growth.

Covidien's quarterly profit fell to $493 million, or $1.03 per share, versus $494 million, or $1.02 per share, in the year-ago period. Excluding one-time items, its adjusted earnings declined to $1.10 per share, versus $1.13 per share.

Its sales gained 5.5% to $3.06 billion. However, analysts were expecting earnings of $1.06 per share on revenue of $3 billion.

Its gross margin declined to 57.5% from 58.7%

Covidien shares closed at $61.67 yesterday.

Posted-In: profitEarnings News Guidance


Related Articles (COV)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→